Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $93.38 Consensus Price Target from Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $93.3846.

Several equities analysts have weighed in on PTGX shares. Truist Financial raised their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. Barclays raised their price objective on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Weiss Ratings downgraded Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday. BTIG Research reiterated a “buy” rating and set a $82.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. Finally, Citigroup boosted their price target on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $83.68, for a total value of $1,673,600.00. Following the transaction, the director directly owned 7,825 shares in the company, valued at approximately $654,796. This represents a 71.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Asif Ali sold 46,203 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the sale, the chief financial officer directly owned 60,320 shares in the company, valued at $5,014,401.60. This represents a 43.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 203,167 shares of company stock worth $16,889,199 in the last ninety days. Company insiders own 4.90% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of PTGX. Smartleaf Asset Management LLC increased its stake in Protagonist Therapeutics by 11.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock valued at $91,000 after purchasing an additional 146 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of Protagonist Therapeutics by 1.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock valued at $1,170,000 after buying an additional 193 shares during the period. Maryland State Retirement & Pension System boosted its holdings in shares of Protagonist Therapeutics by 2.3% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,603 shares of the company’s stock valued at $751,000 after buying an additional 196 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in shares of Protagonist Therapeutics by 8.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock valued at $258,000 after buying an additional 221 shares during the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Stock Performance

PTGX opened at $82.76 on Thursday. The company has a market cap of $5.17 billion, a price-to-earnings ratio of 133.49 and a beta of 2.26. Protagonist Therapeutics has a one year low of $33.70 and a one year high of $96.54. The business’s fifty day moving average is $84.36 and its two-hundred day moving average is $75.78.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.